[go: up one dir, main page]

NO2008003I1 - Rosiglitazone maleate og metformin hydroklorid - Google Patents

Rosiglitazone maleate og metformin hydroklorid

Info

Publication number
NO2008003I1
NO2008003I1 NO2008003C NO2008003C NO2008003I1 NO 2008003 I1 NO2008003 I1 NO 2008003I1 NO 2008003 C NO2008003 C NO 2008003C NO 2008003 C NO2008003 C NO 2008003C NO 2008003 I1 NO2008003 I1 NO 2008003I1
Authority
NO
Norway
Prior art keywords
metformin hydrochloride
rosiglitazone maleate
rosiglitazone
maleate
metformin
Prior art date
Application number
NO2008003C
Other languages
English (en)
Other versions
NO2008003I2 (no
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2008003(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO2008003I1 publication Critical patent/NO2008003I1/no
Publication of NO2008003I2 publication Critical patent/NO2008003I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO2008003C 1997-06-18 2008-04-03 Rosiglitazon maleat og metformin hydroklorid NO2008003I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (2)

Publication Number Publication Date
NO2008003I1 true NO2008003I1 (no) 2008-04-21
NO2008003I2 NO2008003I2 (no) 2010-06-28

Family

ID=26311745

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19996266A NO324993B1 (no) 1997-06-18 1999-12-17 Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.
NO20063000A NO326958B1 (no) 1997-06-18 2006-06-28 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav.
NO2008003C NO2008003I2 (no) 1997-06-18 2008-04-03 Rosiglitazon maleat og metformin hydroklorid
NO20090846A NO20090846L (no) 1997-06-18 2009-02-24 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO19996266A NO324993B1 (no) 1997-06-18 1999-12-17 Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.
NO20063000A NO326958B1 (no) 1997-06-18 2006-06-28 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20090846A NO20090846L (no) 1997-06-18 2009-02-24 Kombinasjon og farmasoytisk blanding for behandling av diabetes samt anvendelse derav

Country Status (39)

Country Link
US (3) US20060100247A1 (no)
EP (2) EP1787646A3 (no)
JP (1) JP2002504137A (no)
KR (2) KR100666591B1 (no)
CN (2) CN1230171C (no)
AP (1) AP1279A (no)
AR (2) AR012998A1 (no)
AT (1) ATE355840T1 (no)
AU (1) AU8539398A (no)
BG (2) BG109398A (no)
BR (1) BR9810172A (no)
CA (1) CA2294582C (no)
CY (2) CY1107643T1 (no)
CZ (1) CZ298469B6 (no)
DE (2) DE69837261T2 (no)
DK (1) DK0996444T3 (no)
DZ (1) DZ2520A1 (no)
EA (1) EA003144B1 (no)
ES (1) ES2284212T3 (no)
HK (1) HK1028193A1 (no)
ID (1) ID23372A (no)
IL (3) IL133142A0 (no)
IN (1) IN189722B (no)
LU (1) LU91356I2 (no)
MA (1) MA26512A1 (no)
MY (1) MY129897A (no)
NL (1) NL300288I2 (no)
NO (4) NO324993B1 (no)
NZ (1) NZ501260A (no)
OA (1) OA11516A (no)
PE (1) PE83199A1 (no)
PL (2) PL195140B1 (no)
PT (1) PT996444E (no)
SI (1) SI0996444T1 (no)
SK (1) SK286029B6 (no)
TR (1) TR199903057T2 (no)
TW (1) TW565449B (no)
UY (1) UY25049A1 (no)
WO (1) WO1998057634A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
ES2204557T3 (es) 1999-04-23 2004-05-01 Smithkline Beecham Plc Derivado de tiazolidindiona y su uso como antidiabetico.
MXPA02004282A (es) 1999-11-03 2003-02-17 Squibb Bristol Myers Co Metodo para tratar la diabetes.
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
ES2290130T3 (es) * 2000-05-01 2008-02-16 Aeropharm Technology, Llc Formulacion de nucleo.
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CN101272805A (zh) * 2005-07-12 2008-09-24 第一三共株式会社 包含PPARγ激动剂的药物组合物
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP1854794A1 (en) * 2006-05-09 2007-11-14 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
US8586607B2 (en) * 2008-07-28 2013-11-19 Syddansk Universitet Compounds for the treatment of metabolic diseases
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US9050292B2 (en) 2011-01-07 2015-06-09 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
CA2860669C (en) 2012-01-06 2022-05-03 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
KR20230095124A (ko) 2012-01-06 2023-06-28 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9709874A (es) * 1995-06-06 1998-03-31 Pfizer N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
WO1999029314A1 (en) * 1997-12-08 1999-06-17 Bristol-Myers Squibb Company Novel salts of metformin and method
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
DZ2520A1 (fr) 2003-02-01
AR012998A1 (es) 2000-11-22
EP1787646A2 (en) 2007-05-23
US20080090881A1 (en) 2008-04-17
PE83199A1 (es) 1999-10-22
DE69837261T2 (de) 2007-11-08
KR100666591B1 (ko) 2007-01-11
KR20010013844A (ko) 2001-02-26
SI0996444T1 (sl) 2007-08-31
KR20060105005A (ko) 2006-10-09
PL195136B1 (pl) 2007-08-31
NO996266L (no) 1999-12-17
SK179299A3 (en) 2000-11-07
DE122007000054I1 (de) 2007-12-13
US20070004780A1 (en) 2007-01-04
BG109398A (bg) 2006-05-31
OA11516A (en) 2004-02-04
ATE355840T1 (de) 2007-03-15
NO20090846L (no) 1999-12-17
JP2002504137A (ja) 2002-02-05
DK0996444T3 (da) 2007-07-02
BR9810172A (pt) 2000-08-08
AU8539398A (en) 1999-01-04
CA2294582C (en) 2008-02-12
EA200000041A1 (ru) 2000-08-28
AP1279A (en) 2004-05-20
PT996444E (pt) 2007-06-08
NZ501260A (en) 2002-09-27
EP0996444B1 (en) 2007-03-07
NO20063000L (no) 1999-12-17
NO324993B1 (no) 2008-01-14
CN1429551A (zh) 2003-07-16
NL300288I1 (nl) 2007-11-01
CY1107643T1 (el) 2012-01-25
NL300288I2 (nl) 2009-06-02
CA2294582A1 (en) 1998-12-23
IL173650A0 (en) 2006-07-05
BG64818B1 (bg) 2006-05-31
CZ298469B6 (cs) 2007-10-10
TR199903057T2 (xx) 2000-04-21
US20060100247A1 (en) 2006-05-11
CN1230171C (zh) 2005-12-07
PL337362A1 (en) 2000-08-14
IN189722B (no) 2003-04-19
CY2007018I1 (el) 2012-01-25
NO996266D0 (no) 1999-12-17
TW565449B (en) 2003-12-11
HK1028193A1 (en) 2001-02-09
AR012995A1 (es) 2000-11-22
MA26512A1 (fr) 2004-12-20
EP0996444A1 (en) 2000-05-03
MY129897A (en) 2007-05-31
ES2284212T3 (es) 2007-11-01
AP9901719A0 (en) 1999-12-31
BG104060A (en) 2000-10-31
CN1114404C (zh) 2003-07-16
NO326958B1 (no) 2009-03-23
CZ9904578A3 (en) 2001-06-13
IL133142A0 (en) 2001-03-19
WO1998057634A1 (en) 1998-12-23
PL195140B1 (pl) 2007-08-31
SK286029B6 (sk) 2008-01-07
CN1260716A (zh) 2000-07-19
LU91356I2 (fr) 2008-01-29
ID23372A (id) 2000-04-20
EA003144B1 (ru) 2003-02-27
IL133142A (en) 2006-06-11
DE69837261D1 (de) 2007-04-19
UY25049A1 (es) 2000-09-29
NO2008003I2 (no) 2010-06-28
EP1787646A3 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
NO2008003I1 (no) Rosiglitazone maleate og metformin hydroklorid
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO982884L (no) Fenyl- og aminofenyl-alkylsulfonamid og ureaderivater
NO20032753D0 (no) Forbindelse og anvendelse derav
DK1231918T3 (da) Hidtil ukendt præparat baseret på en thiazolidindion og metformin og anvendelse deraf
NO20022086L (no) Antidiabetisk formulering og fremgangsmåte
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
DK1233964T3 (da) Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
NO973338D0 (no) N-(4-aryl-tiazol-2-yl)-sulfonamid-derivater og deres anvendelse
NO954239D0 (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
NO992028L (no) N-substituerte 2-cyanopyrrolidiner
NO972983L (no) Sulfonamider og deres anvendelse
FR08C0005I2 (fr) 2-cyanopyrrolidines n-substitues
DK1019358T3 (da) 3,3-diarylpropylaminer, deres anvendelse og fremstilling
DE69811277D1 (de) Aminierungsverfahren
NO995513D0 (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
NO20000682D0 (no) Pakning og dispenser
DK0891938T3 (da) Maskine og fremgangsmåde til stabling
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
NO995560D0 (no) Reologi omforming og omformingsmidler
DE69824255D1 (de) Deformylase
NO983388D0 (no) Trifenylboran-kolofoniumaminaddukt og anvendelse derav
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO20003128D0 (no) Nye p-aminofenylderivater og deres anvendelse
DK1042286T3 (da) Gamme-glutamyl- og beta-aspartyl-holdige immunmodulerende forbindelser og tilhørense fremgangsmåder